We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER: To Be Cost-Effective, Briumvi Should Be 84 Percent Cheaper
ICER: To Be Cost-Effective, Briumvi Should Be 84 Percent Cheaper
TG Therapeutics would have to cut the price of its newly approved multiple sclerosis antibody Briumvi (ublituximab) by up to 84 percent to meet the same cost-effectiveness threshold as other monoclonal antibodies used to treat the disease, according to a report by the Institute for Clinical and Evidence Review (ICER).